Sarkom, 30% diagnosis is wrong, but new research weapon – Medicine

They are rare tumors that in Italy number about 4,000 new cases per year and have the highest peak among children: sarcoma, with a frequency of 5 cases per 100,000 inhabitants per year, includes over 80 different types of tumors that can occur in any part of the body and affect for all age groups, but precisely because of their rarity, in many cases it is difficult to diagnose them, so that 3 out of 10 diagnoses are initially wrong, and currently most of these neoplasms are still "orphans" of certain drugs. New hopes, however, come from research, with promising studies of molecules that could point to the specific possibilities of treating this type of neoplasia.

The International Congress "Ctos 2018" of the Society for connective tissue oncology is dedicated to sarcomas. From today until November 17, leading field experts will meet in Rome to review new experiments and progress in cancer research in tumors. Rare. Expectations are mainly associated with new molecular therapies. Studies conducted, for example, on fibrosarms of infants, explains Silvia Stacchiotti, a medical oncologist at the National Cancer Institute (Int) in Milan, "a congenital disease that represents a change in the specific protein-specific diffusion (TRK), would show that molecular therapy larotrectinib) aimed at this goal, can provide a long-lasting therapeutic response in most patients. "
We also hope to treat another type of sarcoma, a slightly differentiated hormone, with a very unfavorable prognosis and typical for children: a recent study that also participates in the Intt pediatric representing Italy seems to confirm the reduction of the disease using a specific molecular drug (tazemetostat). It appears that the option of immunotherapy opens for sarcoma. For "the first time – an oncologist determines – we can say that not all sarcomas are irresistible for this type of treatment. Particularly, the alveolar sarcoma of soft parts, a very rare and serious tumor, looks good to respond to immunotherapy with atezolizumab."

However, chemotherapy is still basic: "From the 70s to the present, the survival of patients in 5 years without disease has increased by 60%, from 10% to the current 70%, huge progress," says Alessandra Longhi, Head of Chemotherapy Unit of the Musculoskeletal System at Rizzoli's Orthopedic Institute in Bologna – is made possible by chemo-therapy for this type of tumor. " Therefore, there is a "great expectation in the patient community" – emphasizes Ornella Gonzato, President of the Paola Association for Musculoskeletal Tumors Associated with CTOS, and new hopes come from molecular biology: more precisely, more detailed biology research It seems that some types of sarcomas allow the future the possibility of monitoring the disease , during treatment, by simple blood collection for the analysis of circulating DNA tumors. "A step forward that" in addition to a small invasion of control – concluded Gonzád – would mean that patients could hope for a better person underprivileged therapies based on individual response. "